Daily Pharma News - 16 October 2026

CDSCO Waives Export NOC for Approved r-DNA Drugs Sold Under New Brand Names

In a significant ease-of-doing-business move for India's biologics industry, the Central Drugs Standard Control Organisation (CDSCO) has clarified that manufacturers no longer need a separate export No Objection Certificate (NOC) when exporting already-approved recombinant DNA (r-DNA) drugs under a different brand name, provided the composition, manufacturing site and production process remain unchanged. The clarification came through a notice from the Drugs Controller General of India (DCGI) addressed to state drug controllers.

The decision is expected to cut timelines for biologics exports from India, a country that is rapidly expanding its presence in biosimilars and complex biopharmaceuticals. Export NOCs are a key regulatory checkpoint under the Drugs and Cosmetics Rules, and removing this duplicate layer for identical products means Indian manufacturers can respond faster to overseas tenders and licensing deals. For pharmacy students, this is a textbook example of how regulatory harmonisation directly affects India's pharmaceutical trade competitiveness.

Health Ministry Proposes Ban on Prescription Drug Advertising by Retailers and Wholesalers Without Prior Approval

The Union Health Ministry has proposed a draft amendment, GSR 861(E), to the Drugs Rules 1945 that would insert sub-rule (22) under Rule 65, making it mandatory for retailers, wholesalers and distributors to obtain prior sanction from the Central Government before advertising Schedule H, H1 or X medicines. Until now, advertising restrictions on prescription drugs largely covered manufacturers, leaving a gap through which chemists and distributors could promote potent prescription medicines.

The proposal closes a long-standing loophole in Indian drug regulation and reflects growing concern over the irrational promotion of antibiotics, habit-forming and high-risk medicines at the retail level. If finalised, pharmacy retailers will need to align their marketing practices with the same standards that bind manufacturers. For students of pharmacy law and ethics, this draft rule is worth tracking closely - it sits at the intersection of the Drugs and Cosmetics Act, retail pharmacy practice, and public health policy.

Tamil Nadu Health Secretary Urges Pharmacists to Report Spurious and Substandard Drugs

At the Tamil Nadu Pharmacy Council's World Pharmacists Day event in Chennai, Health Secretary Darez Ahamed called on pharmacists to actively report spurious and substandard drugs as well as adverse drug reactions, underscoring the pharmacist's role as a frontline guardian of medicine quality. He also warned against dispensing antibiotics without a valid prescription and stressed the importance of counselling patients who skip their blood pressure medication.

The message is especially relevant in South India, where community pharmacies are often the first and sometimes only point of healthcare contact for patients. Reporting substandard drugs feeds into India's pharmacovigilance network and the CDSCO's quality surveillance, while curbing over-the-counter antibiotic sales is a direct fight against antimicrobial resistance - one of the biggest public health challenges of our time. For pharmacy students, this reinforces a core professional duty: dispensing is not just supply, it is clinical responsibility.

USFDA Issues Form 483 With 3 Observations After Pre-Approval Inspection at Dr Reddy's FTO-9 Plant

Dr Reddy's Laboratories disclosed in a stock exchange filing that the United States Food and Drug Administration (USFDA) completed a pre-approval inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam on October 8-9, 2026, and issued a Form 483 with three observations. The company stated it will respond to the observations within the stipulated timeline; the nature of the observations was not disclosed.

Form 483 observations are issued when USFDA investigators note conditions that may violate current Good Manufacturing Practices (cGMP), and a three-observation 483 after a PAI is generally considered manageable - though the company's response will determine whether the pending product approvals move forward smoothly. For Indian pharma watchers, this is another reminder of how central USFDA compliance is to the fortunes of India's generic drug exporters, with Dr Reddy's being one of the country's largest US-facing manufacturers.

CSPC's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval in China

China's National Medical Products Administration (NMPA) has approved CSPC Pharmaceutical Group to begin clinical trials of SYS6088 injection, a recombinant humanised trispecific antibody simultaneously targeting PD-1, VEGFA and CTLA-4, for the treatment of advanced or metastatic solid tumours. The announcement, dated 15 October 2026, follows preclinical studies that the company says demonstrated favourable safety and broad anti-tumour activity.

Trispecific antibodies represent the next frontier beyond bispecifics, combining immune checkpoint blockade (PD-1, CTLA-4) with anti-angiogenic action (VEGFA) in a single molecule. China's NMPA has been clearing innovative biologics at a rapid pace, and CSPC - one of China's largest drugmakers - is positioning itself in the competitive immuno-oncology space. For pharmacy students studying biopharmaceutics and monoclonal antibody therapeutics, SYS6088 is a live case study in modern antibody engineering.

Russia Registers Elefusa (Fuzuloparib) for Aggressive Breast and Ovarian Cancer

Russia has registered fuzuloparib, marketed as Elefusa, for the treatment of aggressive forms of breast and ovarian cancer, with domestic drugmaker Petrovax Pharm set to supply and manufacture the medicine locally. The company said that bringing production of the active substance into Russia will significantly widen patient access to the therapy.

Fuzuloparib is a PARP (poly ADP-ribose polymerase) inhibitor - a class of targeted cancer drugs that block DNA repair in tumour cells, particularly effective in cancers with defective DNA repair pathways. Already approved in China, its entry into Russia through local manufacturing reflects a broader trend of countries building domestic oncology production capacity. For Indian pharmacy students, this story is doubly relevant: PARP inhibitors like olaparib are already part of India's oncology landscape, and the Russia-China axis of cancer drug development is an increasingly important part of global pharmaceutical geography.

EMA Panel Backs Rasonque (Daraxonrasib) for Metastatic Pancreatic Cancer

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending EU marketing authorisation for Rasonque (daraxonrasib), a RAS inhibitor indicated for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy. Phase 3 trial data showed a median overall survival of 12.4 months versus 6.7 months with chemotherapy - a striking result in one of oncology's hardest-to-treat cancers.

Pancreatic cancer has one of the lowest five-year survival rates of any solid tumour, and RAS mutations - long considered "undruggable" - drive the vast majority of cases. A positive CHMP opinion typically leads to formal European Commission approval within weeks, and the data could reshape treatment guidelines for previously treated metastatic pancreatic cancer. For pharmacy students, daraxonrasib illustrates the payoff of decades of medicinal chemistry aimed at the RAS target, and a positive CHMP opinion is a milestone worth understanding in the EU regulatory pathway.

Conclusion

Today's news spans the full spectrum of modern pharmacy: Indian regulators streamlining biologics exports and tightening prescription drug advertising, Tamil Nadu's pharmacists being reminded of their clinical duty, a major Indian manufacturer navigating USFDA scrutiny, and breakthrough oncology science moving through regulators in China, Russia and Europe. The common thread is the pharmacist's expanding role - from supply chain and law to pharmacovigilance and patient counselling. For pharmacy students, staying current with stories like these is not optional reading; it is the context in which every future prescription, inspection and counselling session will happen.

References

← All daily news